Proteomics International (ASX:PIQ) - Managing Director, Dr Richard Lipscombe
Managing Director, Dr Richard Lipscombe
Source: Proteomics International
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Proteomics International Laboratories (PIQ) engages Biotem to manufacture its test kits
  • The test can predict future kidney function decline in patients with type 2 diabetes and no existing diabetic kidney disease using a simple blood test
  • The agreement spans over three years, with the option to extend for additional periods of one year
  • Proteomics shares were up 8.61 per cent, trading at $1.14 at 3:50 pm AEST

Proteomics International Laboratories (PIQ) has contracted a French immunoassay specialist to manufacture its test kits.

The company, Biotem, has been contracted to manufacture test kits for the PromarkerD predictive test for diabetic kidney disease, using a ‘fingerprint’ of protein biomarkers in the blood.

The test can predict future kidney function decline in patients with type 2 diabetes and no existing diabetic kidney disease using a simple blood test.

“Now, by contracting these specialist manufacturers we are building our production capacity to meet our anticipated demand for the test in the Northern Hemisphere and worldwide,” said Proteomics’ managing director, Dr Richard Lipscombe.

The agreement spans over three years, with the option to extend for additional periods of one year. During this time, Biotem will manufacture PromarkerD test kits on a fee-for-service basis.

The announcement follows reagent producer, Abcam being contracted for a world first predictive test for diabetic kidney disease.

“The engagement of global manufacturing partners will help accelerate the worldwide roll-out of PromarkerD, as well as the commercialisation of our pipeline of other diagnostics under development,” said Dr Lipscombe.

Proteomics shares were up 8.61 per cent, trading at $1.14 at 3:50 pm AEST.

piq by the numbers
More From The Market Online

Emvision Medical Devices unlocks traumatic brain injury First Responder with $3m grant

EMVision Medical Devices has been awarded a $3 million grant the Australian government’s national CRC-P program.

Immutep obtains encouraging disease-free survival in phase II sarcoma trial

Immutep has unveiled new data from the investigator-initiated EFTISARC-NEO Phase II study evaluating radiotherapy before surgery.

Xenitra signs JD Health strategic Chinese agreement targeting $100m in sales

Xenitra subsidiary Shengdi Pharmaceutical has entered into a three-year strategic agreement with China’s largest online healthcare…

Racura Oncology receives positive results in study of RC110 and RC220

Racura Oncology has obtained positive results from a study into RC220, the company’s proprietary formulation of…